OBI announces the termination of OBI-3424-001 trial while continuing the collaboration of OBI-3424 with partners

1.Date of occurrence of the event:2024/03/11 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: Following …

Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA

1.Date of occurrence of the event:2024/02/29 2.New drug name or code:OBI-858 Novel Botulinum Neurotoxin 3.Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic …

Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

1.Date of occurrence of the event:2024/01/31 2.New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 3.Indication: Adagloxad Simolenin (OBI-822) is a therapeutic cancer vaccine classified as an …

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody –  drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial …

OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

1.Date of occurrence of the event:2024/01/03 2.New drug name or code: OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment that is based on TROP2 …

Announcement on behalf of Amaran that its institutional director changes its representative

1.Date of occurrence of the change:2023/12/29 2.Name of legal person: OBI Pharma Inc. 3.Name of the previous position holder: Chen-En Tsai 4.Resume of the previous position holder: Vice president of …

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

OBI Pharma, Inc. (4174.TWO) held a board meeting today (29th) and unanimously elected Kung-Yee Liang PH.D., the new legal representative, former president of the National Health Research Institutes (NHRI), and …

The Company’s Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board

1.Date of the board of directors resolution or date of occurrence of the change:2023/12/29 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the previous position holder: Yun Yen …

Announcement on behalf of OBIGEN that its institutional director changes its representative

1.Date of occurrence of the change:2023/12/29 2.Name of legal person: OBI Pharma Inc. 3.Name of the previous position holder: Yun Yen 4.Resume of the previous position holder: Chairperson of the …

Announcement that the institutional director of OBI, Sheng Cheng Investment Co., Ltd., changes its representative

1.Date of occurrence of the change:2023/12/21 2.Name of legal person: Sheng Cheng Investment Co., Ltd. 3.Name of the previous position holder: Frank Chen 4.Resume of the previous position holder: Vice …